SHARPE
Reported results
- Total PSEG GAAP Net Income for Q3 2026 was $376 million, or $0.76 per share, compared to $622 million, or $1.24 per share, in Q3 2025.
- Total PSEG non-GAAP Operating Earnings for Q3 2026 were $574 million, or $1.15 per share, compared to $565 million, or $1.13 per share, in Q3 2025.
- For the nine months ended September 30, 2026, GAAP Net Income was $1,451 million, or $2.91 per share, compared to $1,796 million, or $3.59 per share, for the nine months ended September 30, 2025.
- For the nine months ended September 30, 2026, non-GAAP Operating Earnings were $1,777 million, or $3.56 per share, compared to $1,667 million, or $3.33 per share, for the nine months ended September 30, 2025.
- Regulated investment was ~$1.1 billion in Q3 2026.
Guidance
- PSEG is maintaining its 2026 non-GAAP Operating Earnings guidance of $4.28 - $4.40 per share.
- PSEG’s outlook for long-term, non-GAAP Operating Earnings CAGR is 6%-8% through 2030.
- Regulated capital spending plan for full year 2026 is ~$4.2 billion.
- Total PSEG capital spending program is $24B - $28B for 2026-2030.
- For 2026, total nuclear generation is forecasted to be 30-32 TWh.
Price and volatility reaction
The stock moved +0.1% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved +0.2 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 74.29 | 2026-10-30 |
| Close after release | 74.38 | 2026-11-02 |
| Realised move | +0.1% | close to close |
| 30d ATM IV change | +0.2 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-02 (8-K, Item 2.02). Read the original filing on sec.gov.